They carve the path towards the goal. The executive team combines their different skills and expertise to bring the company’s vision to life.
Chief Executive Officer
Reason is co-founder and CEO of Repair Biotechnologies. He has been an active angel investor in the longevity industry since its earliest days, and is a long-standing and well-connected patient advocate…
Reason is co-founder and CEO of Repair Biotechnologies. He has been an active angel investor in the longevity industry since its earliest days, with investments including Oisin Biotechnologies and Leucadia Therapeutics. He is a long-standing and well-connected patient advocate for aging research, involved in numerous fundraising and outreach initiatives conducted by organizations such as the Methuselah Foundation and SENS Research Foundation since the early 2000s. He is also the founder and writer of Fight Aging!, a noted news and commentary website in the biotechnology community. Prior to his involvement in the biotechnology industry, Reason was a consultant in the software industry. He holds Masters degrees in Astrophysics from the University of St. Andrews and Space Physics from Rice University.
Mourad Topors, PhD
Chief Scientific Officer
Mourad Topors is the Chief Scientific Officer of Repair Biotechnologies. He has deep experience in leading and managing multi-disciplinary teams in translational medical research with a strong focus in cardiovascular disease. Formerly, Dr. Topors was Principal Investigator and Faculty at Harvard Medical School and served as Team Leader of a drug development program at Pfizer’s Center for Therapeutic Innovations. He holds a PhD in Experimental Medicine from McGill University and a postdoctoral fellowship in the Department of Immunology at the University of Toronto.
Bobby Khan, MD, PhD
Chief Medical Officer
Bobby Khan is the Chief Medical Officer of Repair Biotechnologies. He is a cardiologist and clinical investigator, serving as Professor of Medicine at the University of Central Florida School of Medicine. Dr. Khan has published nearly 90 peer-reviewed articles in the areas of cardiovascular and metabolic disorders in highly regarded scientific journals. He is co-founder of Carmel Biosciences, which was successful in receiving its first approved product by the United States Food and Drug Administration in early 2018. Dr. Khan has served as the principal investigator for several clinical trials.